Information Provided By: 
Fly News Breaks for September 15, 2015
MYGN
Sep 15, 2015 | 05:44 EDT
Piper Jaffray analyst William Quirk calls Myriad Genetics' analyst day yesterday a "very positive event" and raised his price target for shares to $45 from $41. Myriad guided to greater than 10% annual revenue growth and greater than 30% operating margin by fiscal year 2020, which translates into $1.5B in revenue and $3.75-$4.00 in earnings per share, without incremental share buybacks or acquisitions, Quirk tells investors in a research note. The analyst reiterates an Overweight rating on the stock.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
